  As the world's first primary morbidity factor, depression has a considerable
impact on both an individual as well as a societal level. despite their
discovery several decades ago, classical antidepressants have been shown to
provide limited benefits against this condition. However, substances such as
ketamine and psychedelics have recently shown promising results and even
received the grade of Breakthrough therapy for this indication. The accurate
mechanisms of action underlying the efficacy of these substances are still to
be defined, but some similarities appear to be shared on different levels
across these substances. These include their structural, functional and
behavioral plasticity promoting abilities, as well as their capacity to promote
Brain-Derived Neurotrophic Factor overexpression, which seems to constitute a
key element underlying their immediate and long-lasting action. From this
observation, the present review aims to examine and connect the pharmacological
pathways involved in these therapies to the neurobiological, cognitive and
psychological responses that could be shared by both 5-HT2AR agonists and NMDA
antagonists. It is suggested that BDNF overexpression resulting from mTOR
activation mediates both structural and functional plasticity, resulting in
connectivity changes among high-level cognitive networks such as the Default
Mode Network, finally leading to an increased and long-lasting psychological
flexibility. Connecting these pieces of evidence could provide insights about
their precise mechanisms of action and help researchers to develop biomarkers
for antidepressant response. If the hypotheses suggested in this review are
verified by further trials, they could also constitute a starting point to
developing safer and more efficient antidepressants, as well as provide
information about the interactions that exist between different
neurotransmitters systems.
